Billion-dollar autoimmune drug deal a ‘dream come true’ for Calgary researcher

With autoimmune diseases, the body’s own tissues are mistaken for harmful invaders and attacked

Dr. Pere Santamaria, a professor in the Department of Microbiology, Immunology and Infectious Diseases, and member of the university’s Snyder Institute for Chronic Diseases, poses in this undated handout photo. Parvis Therapeudics, the company Santamaria founded, and California-based company Genetech have reached a billion-dollar deal to develop a potential treatment for celiac disease, irritable bowel syndrome and other autoimmune diseases. THE CANADIAN PRESS/HO - University of Calgary, Riley Brandt

A University of Calgary researcher says he’s hopeful a deal worth up to $1 billion between his drug company and a U.S. biotechnology firm could one day lead to autoimmune disease treatments that don’t make patients more vulnerable to infections or cancer.

“It’s kind of a dream come true that I can play a role in this process and realize something that might perhaps help a lot of people,” said Pere Santamaria, founder of Parvus Therapeutics and a professor at the university’s Cumming School of Medicine.

Parvus announced a working and licensing agreement Thursday with California-based Genentech to develop, manufacture and commercialize a class of drugs known as Navacims to potentially treat celiac, autoimmune liver and inflammatory bowel diseases.

Parvus is to get an upfront payment from Genentech and further payments as certain milestones are reached. The companies are not disclosing precisely how the funds are to be broken down or over what time period. Parvus is also eligible to get royalty payments on sales that result from the deal.

READ MORE: Legalization sparks boom in field of marijuana research

The immune system is meant to protect the body from bacteria, viruses and cancer. But in people with autoimmune diseases, the body’s own tissues are mistaken for harmful invaders and attacked.

Current treatments work by suppressing the immune system as a whole, which makes patients less able to fight off infections and cancer.

Navacims, discovered by Santamaria and his team in 2004, use nanoparticles to switch off autoimmune attacks in a way that doesn’t compromise the body’s overall disease-fighting abilities.

Santamaria said the treatments have been tested extensively in mice with promising results. The deal with Genentech will go toward clinical trials in humans. Parvus will be responsible for initial small-scale tests. Genentech will take on subsequent studies in larger groups and, if successful, the regulatory work needed to bring the drug to market.

The companies aren’t disclosing when the trials will be done, but Santamaria said time is of the essence.

“It’ll take some time, but resources will be brought to bear so that this can be accelerated as fast as we can to get these drugs to patients in need.”

Parvus teamed up with another drug firm, Novartis, in 2017 to develop Navacims as a potential treatment for Type 1 diabetes.

Santamaria said bringing Navacims to market without the resources and know-how from larger partners would be inconceivable.

“It’s been a tough, long haul with a lot of challenges and hurdles in many aspects.”

University of Calgary president Ed McCauley said the big-ticket investment affirms how important it is to invest in fundamental research.

“It’s incredible,” he said. “The discoveries we are making are actually being mobilized to help society.”

Lauren Krugel, The Canadian Press

Like us on Facebook and follow us on Twitter

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

Alberta confirms 29 new COVID-19 cases

Of the total 6,955 confirmed cases, 652 are active

No increase in property taxes for Sylvan Lake residents

Town Council passes the 2020 Tax Bylaw at Monday’s council meeting

PHOTOS: Sylvan Lake teachers say hello to students at drive through

Ecole Mother Teresa School arranged a drive through for families to say hello to their teachers

Sylvan Lake Community Partners seeking donations

Community Partners is still open and ready to help, says Jen Baliant

Facing changes together: Your community, your journalists

Sylvan Lake News is firmly committed to seeing you through the changes ahead, but we need your help

Facing changes together: Your community, your journalists

Sylvan Lake News is firmly committed to seeing you through the changes ahead, but we need your help

More hospitals part of plasma transfusion trial to treat COVID-19 with antibodies

More hospitals part of plasma transfusion trial to treat COVID-19 with antibodies

Brazilians say ‘I do’ at drive-thru weddings to avoid virus

Brazilians say ‘I do’ at drive-thru weddings to avoid virus

Cases going down, but experts urge against visiting grandparents during pandemic

Cases going down, but experts urge against visiting grandparents during pandemic

One dead, four hurt in head-on crash on one-way street in Edmonton

One dead, four hurt in head-on crash on one-way street in Edmonton

NDP mocks Alberta premier’s UCP for taking COVID cash from ‘sugar daddy’ Trudeau

NDP mocks Alberta premier’s UCP for taking COVID cash from ‘sugar daddy’ Trudeau

Alberta introduces bill to change rules on charter schools, home-schooling

Alberta introduces bill to change rules on charter schools, home-schooling

Opposition parties call on Liberals to restore human-trafficking victims fund

Opposition parties call on Liberals to restore human-trafficking victims fund

Most Read